Ursula Vogl

1.1k total citations · 1 hit paper
20 papers, 878 citations indexed

About

Ursula Vogl is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, Ursula Vogl has authored 20 papers receiving a total of 878 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 8 papers in Cancer Research and 7 papers in Oncology. Recurrent topics in Ursula Vogl's work include Renal cell carcinoma treatment (16 papers), Cancer Genomics and Diagnostics (6 papers) and Renal and related cancers (5 papers). Ursula Vogl is often cited by papers focused on Renal cell carcinoma treatment (16 papers), Cancer Genomics and Diagnostics (6 papers) and Renal and related cancers (5 papers). Ursula Vogl collaborates with scholars based in Austria, Switzerland and United States. Ursula Vogl's co-authors include Manuela Schmidinger, Marija Bojić, Christoph Zielinski, Michael Hejna, Andja Bojic, Christoph Schukro, Herwig Schmidinger, Andrea Haitel, Wolfgang Lamm and Gero Kramer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

Ursula Vogl

17 papers receiving 863 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma

2008 486 citations Manuela Schmidinger, Christoph Zielinski et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ursula Vogl Austria	9	417	397	341	297	171	20	878
Mimma Rizzo Italy	17	696 1.7×	428 1.1×	484 1.4×	113 0.4×	333 1.9×	78	1.1k
Tammy F. Chu United States	4	280 0.7×	461 1.2×	328 1.0×	635 2.1×	71 0.4×	6	1.0k
Jey-Hsin Chen United States	6	256 0.6×	481 1.2×	269 0.8×	498 1.7×	69 0.4×	11	1.1k
Pier Vitale Nuzzo United States	16	500 1.2×	389 1.0×	382 1.1×	104 0.4×	298 1.7×	58	943
Helen Musgrove United Kingdom	6	289 0.7×	415 1.0×	441 1.3×	55 0.2×	158 0.9×	7	852
S. Srinivas United States	13	527 1.3×	282 0.7×	410 1.2×	137 0.5×	264 1.5×	38	816
Pooja Ghatalia United States	20	653 1.6×	517 1.3×	633 1.9×	145 0.5×	330 1.9×	81	1.4k
Marilyn Mulay United States	11	250 0.6×	365 0.9×	243 0.7×	66 0.2×	104 0.6×	17	644
Jan Cosaert United States	17	644 1.5×	1.1k 2.7×	438 1.3×	132 0.4×	336 2.0×	43	1.5k
Angel H. Bair United States	13	704 1.7×	435 1.1×	559 1.6×	75 0.3×	330 1.9×	17	1.0k

Countries citing papers authored by Ursula Vogl

Since Specialization

Citations

This map shows the geographic impact of Ursula Vogl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ursula Vogl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ursula Vogl more than expected).

Fields of papers citing papers by Ursula Vogl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ursula Vogl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ursula Vogl. The network helps show where Ursula Vogl may publish in the future.

Co-authorship network of co-authors of Ursula Vogl

This figure shows the co-authorship network connecting the top 25 collaborators of Ursula Vogl. A scholar is included among the top collaborators of Ursula Vogl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ursula Vogl. Ursula Vogl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lorch, Anja, et al.. (2024). PD-L1 expression and correlation with outcome in muscle-invasive and metastatic urothelial carcinoma: review and critical discussion. Frontiers in Oncology. 14.

Schneider, Ralph P., et al.. (2023). Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland. PharmacoEconomics - Open. 7(4). 567–577. 3 indexed citations

Vogl, Ursula, Laurenz Vormittag, Thomas Winkler, et al.. (2020). Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma—experience at two centres. Journal of Gastrointestinal Oncology. 11(2). 366–375. 7 indexed citations

Schmidinger, Manuela, Renate Pichler, Wolfgang Loidl, et al.. (2019). Real-World Evidence Data on Metastatic Renal-Cell Carcinoma Treatment in Austria: The RELACS Study. Clinical Genitourinary Cancer. 17(5). e957–e967. 9 indexed citations

Vogl, Ursula, Alexander Klaus, Laurenz Vormittag, et al.. (2019). Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?. BMC Cancer. 19(1). 28–28. 42 indexed citations

Vogl, Ursula. (2019). Second-line therapy in metastatic renal cell cancer—how do we treat after immuno-oncology drugs?. memo - Magazine of European Medical Oncology. 12(4). 339–341.

Vogl, Ursula, Gerda Leitner, Assunta Dal‐Bianco, et al.. (2016). Complete neurologic and cognitive recovery after plasmapheresis in a patient with chronic inflammatory demyelinating polyneuropathy after allogeneic hematopoietic stem cell transplantation. Wiener klinische Wochenschrift. 128(9-10). 384–386. 2 indexed citations

Prummer, Michael, Qing Zhong, Jens Bedke, et al.. (2016). MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients. Oncotarget. 7(48). 78433–78447. 25 indexed citations

Vogl, Ursula, Lothar Ponhold, Gottfried J. Locker, et al.. (2013). Safety and efficacy of axitinib in pretreated patients with metastatic renal cell carcinoma: A single center experience of the Medical University of Vienna, Austria.. Journal of Clinical Oncology. 31(15_suppl). e15535–e15535.

10.

Schmidinger, Manuela, Marija Bojić, Ursula Vogl, et al.. (2012). Safety and efficacy of pazopanib in heavily pretreated and treatment-naive patients with metastatic renal cell carcinoma (mRCC): A single center experience of the Medical University of Vienna, Austria.. Journal of Clinical Oncology. 30(15_suppl). e15090–e15090. 1 indexed citations

11.

Lamm, Wolfgang, Ursula Vogl, Marija Bojić, et al.. (2011). Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma. Acta Oncologica. 51(1). 101–106. 7 indexed citations

12.

Schmidinger, Manuela, Ursula Vogl, Marija Bojić, et al.. (2010). Hypothyroidism in patients with renal cell carcinoma. Cancer. 117(3). 534–544. 159 indexed citations

13.

Vogl, Ursula, Marija Bojić, Wolfgang Lamm, et al.. (2010). Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma. BMC Cancer. 10(1). 480–480. 23 indexed citations

14.

Elandt, Katarzyna, Matthias Preusser, Karin Dieckmann, et al.. (2010). Treatment with bevazicumab and liposomal doxorubicin for recurrent high-grade gliomas (HGGs).. Journal of Clinical Oncology. 28(15_suppl). e12522–e12522. 1 indexed citations

15.

Schmidinger, Manuela, Andja Bojic, Ursula Vogl, Wolfgang Lamm, & Christoph Zielinski. (2009). Management of cardiac adverse events occurring with sunitinib treatment.. PubMed. 29(5). 1627–9. 6 indexed citations

16.

Vogl, Ursula, Walter Berger, M. Micksche, et al.. (2009). Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines. Cancer Letters. 277(2). 218–226. 9 indexed citations

17.

Schmidinger, Manuela, Ursula Vogl, Wolfgang Lamm, et al.. (2008). Temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma: Preliminary results from the Austrian Compassionate Use Program. Journal of Clinical Oncology. 26(15_suppl). 16125–16125. 9 indexed citations

18.

Schmidinger, Manuela, Christoph Zielinski, Ursula Vogl, et al.. (2008). Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 26(32). 5204–5212. 486 indexed citations breakdown →

19.

Schmidinger, Manuela, Ursula Vogl, Christoph Schukro, et al.. (2007). Cardiac involvement in patients with sorafenib or sunitinib treatment for metastatic renal cell carcinoma. Journal of Clinical Oncology. 25(18_suppl). 5110–5110. 4 indexed citations

20.

Vogl, Ursula, Harald Zehetgruber, Martin Dominkus, et al.. (2006). Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. British Journal of Cancer. 95(6). 691–698. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact